PPD, Inc. Confirms Takeda Pharmaceutical Co. Ltd.'s NDA Submission of Alogliptin and ACTOS® to U.S. FDA

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPDI) today confirmed that Takeda Pharmaceutical Company Limited has submitted a new drug application to the U.S. Food and Drug Administration for marketing approval of alogliptin (SYR-322) and ACTOS® (pioglitazone HCl) in a single tablet for the treatment of type 2 diabetes.

Back to news